ERBB2 and head and neck squamous cell carcinoma: The rationale for combining afatinib with cetuximab in R/M HNSCC is based on preclinical studies showing that resistance to EGFR inhibition frequently arises through compensatory signaling mediated by other ErbB family members, particularly HER2 and HER3 [92].